Clinical Trial Update: A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial SEASTAR evaluating rucaparib in combination with other anticancer agents in solid tumors; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Solid Tumor
• Triple-negative Breast Cancer
• Urothelial Carcinoma

Drugs mentioned

• Rucaparib (rucaparib)

Snippet

Sponsor: pharmaand GmbH | Conditions: Ovarian Cancer, Triple-negative Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-01-16